Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks *et al*

Sparks *et al*¹ are to be congratulated on an important and timely study. They found that the use of JAKi was associated with worse outcome of COVID-19 infection, and they interpret this as a harmful effect of the treatment in that particular setting. But this question deserves further consideration. Assuming that the observation is correct, what could the mechanism be? As the authors correctly point out, some JAKi's did show benefits for patients with severe COVID-19 infection.^{2,3} We, therefore, propose an alternative explanation of the observed data.

Some guidance documents,^{4,5} and certainly medical practice traditions, frequently have patients discontinue immunomodulatory treatments when a potentially severe infection is diagnosed, and it seems safe to assume that the vast majority of patients in the study did, in fact, stop their treatment when they became aware of the infection. While this would of course apply to all antirheumatic therapies, there are important differences in the impact this might have. Biologicals have half-lives in the order of weeks, and the effect of stopping the treatment is, therefore, limited in the acute setting. For methotrexate, pharmacodynamic aspects also lead to a long latency in the impact of discontinuing the drug. In contrast, JAKi have short half-lives and discontinuing the treatment will almost immediately lead to the reactivation of the relevant signalling pathways.

We therefore propose, as an alternative possible explanation of the findings by Sparks *et al*, that it is the discontinuation of JAKi when SARS-CoV-2 infection is diagnosed, rather than the treatment itself, that is harmful.

Needless to say, this possibility needs to be tested in clinical studies before leading to changes in practice, and would most likely only be addressed sufficiently in a prospective, randomised trial.

Ronald F van Vollenhoven ¹, Sander W Tas,² Michael T Nurmoehamed ³

¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands

²Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands

³Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands

Correspondence to Dr Ronald F van Vollenhoven, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands; r.vanvollenhoven@amsterdamumc.nl

Contributors All authors contributed to the concept and critically reviewed the manuscripts.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite van Vollenhoven RF, Tas SW, Nurmoehamed MT. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2021-221146

Received 13 July 2021

Accepted 13 July 2021

► <http://dx.doi.org/10.1136/annrheumdis-2021-221157>

Ann Rheum Dis 2021;**0**:1. doi:10.1136/annrheumdis-2021-221146

ORCID iDs

Ronald F van Vollenhoven <http://orcid.org/0000-0001-6438-8663>

Michael T Nurmoehamed <http://orcid.org/0000-0002-6274-1934>

REFERENCES

- 1 Sparks JA, Wallace ZS, Seet AM. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry. *Ann Rheum Dis* 2021. doi:10.1136/annrheumdis-2021-eular.1632. [Epub ahead of print: 28 May 2021].
- 2 Kalil AC, Patterson TF, Mehta AK. ACTT-2 Study Group members. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. *N Engl J Med* 2021;384:795–807.
- 3 Guimarães PO, Quirk D, Furtado RH, *et al*. Tofacitinib in patients hospitalized with Covid-19 pneumonia. *N Engl J Med Overseas Ed* 2021.
- 4 Landewé RB, Machado PM, Kroon F, *et al*. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. *Ann Rheum Dis* 2020;79:851–8.
- 5 Leipe J, Hoyer BF, Iking-Konert C, *et al*. SARS-CoV-2 & Rheuma. *Z Rheumatol* 2020;79:686–91.